Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Connelly, 1987, Demographic patterns for mesothelioma in the United States, J Natl Cancer Inst, 78, 1053

Zellos, 2002, Multimodality treatment of diffuse malignant pleural mesothelioma, Semin Oncol, 29, 41, 10.1053/sonc.2002.30230

Antman, 1988, Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985, J Clin Oncol, 6, 147, 10.1200/JCO.1988.6.1.147

Vogelzang, 2003, Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, 21, 2636, 10.1200/JCO.2003.11.136

Kelly, 2001, Suberoylanilide hydroxamic acid (SAHA), a Histone Deacetylase inhibitor: Biologic activity without toxicity, Proc Am Soc Clin Oncol, 20, A344

Richon, 1998, A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases, Proc Natl Acad Sci U S A, 95, 3003, 10.1073/pnas.95.6.3003

Yoshida, 1990, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, J Biol Chem, 265, 17174, 10.1016/S0021-9258(17)44885-X

Krug, 2006, Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid, Clin Lung Cancer, 7, 257, 10.3816/CLC.2006.n.003

Neuzil, 2004, Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation, Biochem Biophys Res Commun, 314, 186, 10.1016/j.bbrc.2003.12.074

Deroanne, 2002, Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling, Oncogene, 21, 427, 10.1038/sj.onc.1205108

Linder, 1998, Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma, Anticancer Res, 18, 2063

Buckley, 2007, The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo, J Transl Med, 5, 49, 10.1186/1479-5876-5-49

Qian, 2008, Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer, Int J Cancer, 122, 1400, 10.1002/ijc.23243

Plumb, 2003, Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Mol Cancer Ther, 2, 721

Steele, 2008, A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors, Clin Cancer Res, 14, 804, 10.1158/1078-0432.CCR-07-1786

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9

Luu, 2008, A phase II trial of virnostat (suberoylanilide hydroxamic acid) in metastic breast cancer: A California Consortium study, Clin Cancer Res, 14, 7138, 10.1158/1078-0432.CCR-08-0122

Blumenschein, 2008, Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer, Invest New Drugs, 26, 81, 10.1007/s10637-007-9075-2

Traynor, 2007, A phase II study of vorinostat (NSC 701852) in patients (pts) with relapsed non-small cell lung cancer (NSCLC), J Clin Oncol, 25